The stock of Synairgen plc (LON:SNG) gapped up by GBX 0.48 today and has GBX 46.44 target or 158.00% above today’s GBX 18.00 share price. The 8 months technical chart setup indicates low risk for the GBX 17.16M company. The gap was reported on Nov, 8 by Barchart.com. If the GBX 46.44 price target is reached, the company will be worth GBX 27.11 million more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. The stock increased 5.88% or GBX 1 on November 8, hitting GBX 18. About 64,453 shares traded hands. Synairgen plc (LON:SNG) has declined 33.33% since April 8, 2016 and is downtrending. It has underperformed by 35.29% the S&P500.
Synairgen plc (LON:SNG) Ratings Coverage
Out of 2 analysts covering Synairgen PLC (LON:SNG), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Synairgen PLC has been the topic of 12 analyst reports since July 22, 2015 according to StockzIntelligence Inc. N+1 Singer maintained it with “Buy” rating and GBX 49 target price in Wednesday, August 5 report. The rating was maintained by FinnCap on Tuesday, August 30 with “Corporate”. FinnCap maintained Synairgen plc (LON:SNG) rating on Wednesday, August 5. FinnCap has “Corporate” rating and GBX 127 price target. The rating was maintained by FinnCap on Thursday, September 22 with “Corporate”. N+1 Singer maintained Synairgen plc (LON:SNG) rating on Wednesday, September 16. N+1 Singer has “Buy” rating and GBX 49 price target. The stock has “Corporate” rating given by FinnCap on Tuesday, March 22. The stock of Synairgen plc (LON:SNG) earned “Corporate” rating by FinnCap on Wednesday, October 12. The company was maintained on Wednesday, September 16 by FinnCap. As per Wednesday, July 22, the company rating was maintained by N+1 Singer. The firm has “Buy” rating by N+1 Singer given on Thursday, January 28.
More recent Synairgen plc (LON:SNG) news were published by: Reuters.com which released: “Synairgen slumps by a third as AstraZeneca ditches asthma drug study” on October 12, 2016. Also Marketwatch.com published the news titled: “Synairgen PLC” on June 10, 2011. Fool.Co.Uk‘s news article titled: “Are Synairgen plc or Immupharma plc better investments than AstraZeneca plc?” with publication date: June 07, 2016 was also an interesting one.
Synairgen plc is a holding company. The Firm is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (IPF). The company has a market cap of 17.16 million GBP. The Firm uses its human biology BioBank platform to discover and develop therapies for respiratory disease. It currently has negative earnings. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.